HOME / Technology Platforms / Single Cell Technology Platform
Technical features

Single Cell Technology Platform

Harbour Mice®

Bispecific Antibodies

Back to list

Harbour Biomed has set up single cell technology since early 2019. By utilizing the optofluidic technology, we established full process of single B cell cloning from murine CD138+ plasma cell enrichment, single B cell separation in chip, antibody binding and functional in-chip screening methods, single cell antibody sequencing, high throughput recombinant antibody production and verification, etc. Comparing to the traditional monoclonal antibody screening technology, the single B cell cloning as an advanced new technology can greatly increase the efficiency and productivity of antibody drug discovery.

 

 

 

 

 

 

Harbour BioMed has established a robust pipeline in oncology and immunology since the company was established in 2016. The current portfolio includes five clinical-stage in-licensed compounds and a rapidly emerging set of therapeutics coming from its internal discovery efforts as well as co-discovery/development collaborations with academic institutions and biopharmaceutical companies.

contact us